Combatting the 21st century global public health problems through revolutionary i-αVLP Technology.

1210, 2016

VLP Therapeutics was featured in Nikkei Biotech Online (October 11, 2016)

VLP Therapeutics was featured in Nikkei Biotech Online (October 11, 2016).

510, 2016

VLP Therapeutics Receives Grant from Global Health Innovative Technology (GHIT) Fund to Develop New Vaccine for Dengue Fever

Gaithersburg, Md.-- (PR NEWS WIRE) — October 5, 2016 -- VLP Therapeutics, LLC. announced today that it has received a grant for approximately US$960,000 from the Global Health Innovative Technology Fund (“the GHIT Fund”) for

1407, 2016

VLP Therapeutics Wins $2.4M U.S. Army Medical Research Grant

Gaithersburg, Md.-- (PR NEWS WIRE) — July 14, 2016 -- VLP Therapeutics, LLC. (“VLP”), a Gaithersburg-based biotechnology company focusing on the research and development of therapeutic and preventative vaccines and next generation antibody agents based

Vaccines are one of the most important inventions in the past centuries. The successful vaccines save millions of lives by eradicating the epidemic and pandemic diseases. I left the research field and formed VLP Therapeutics because I am committed to developing the next generation vaccine technology to treat the diseases that currently lack effective treatment. We believe that our i-αVLP vaccine technology has a potential to create a breakthrough treatments and make significant contributions to the improvement of global public health.